Hyderabad, Nov 27 (UNI) Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Hetero, one of India’s leading generic pharmaceutical companies have agreed to produce over 100 million doses of world's first registered Sputnik V Vaccine per year in India against the Novel Coronavirus infection.
The parties intend to start the production of Sputnik V in the beginning of 2021, a release here said on Friday.
The Gamaleya Center and RDIF had announced on November 24 about the positive results obtained during the second interim data analysis of the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers.